ArticleAnnals of the New York Academy of Sciences2021

A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways.

Kevin Klein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.